493 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Sell
Article Searches
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
GlaxoSmithKline (GSK) CEO Emma Walmsley on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4238727-glaxosmithkline-gsk-ceo-emma-walmsley-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 06, 2019 - GlaxoSmithKline (NYSE:GSK) Q4 2018 Results Conference Call February 06, 2019 09:00 AM ET Company Participants Sarah Elton-Farr - Head of Investor Relations Emma Walmsley - Chief Executive Officer Simo
GlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/06/glaxosmithkline-plc-gsk-q4-2018-earnings-conferenc.aspx?source=iedfolrf0000001 Feb 06, 2019 - GSK earnings call for the period ending December 31, 2018.
Earnings Data Deluge http://www.zacks.com/stock/news/352615/earnings-data-deluge?cid=CS-ZC--352615 Feb 06, 2019 - Earnings Data Deluge
Big Q4 Numbers & New Trade Data http://www.zacks.com/stock/news/352613/big-q4-numbers-new-trade-data?cid=CS-ZC-FT-352613 Feb 06, 2019 - Plenty of Q4 earnings numbers join new Manufacturing and Trade data, some of which had been previously delayed due to the government shutdown.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/352026/gilead-gild-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-352026 Feb 05, 2019 - A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.
What's in the Cards for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/351786/whats-in-the-cards-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-351786 Feb 04, 2019 - Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
Mylan's Generic Version of Advair Diskus Wins FDA Approval http://www.zacks.com/stock/news/351685/mylans-generic-version-of-advair-diskus-wins-fda-approval?cid=CS-ZC-FT-351685 Feb 01, 2019 - Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.
GlaxoSmithKline (GSK) Flat As Market Gains: What You Should Know http://www.zacks.com/stock/news/351676/glaxosmithkline-gsk-flat-as-market-gains-what-you-should-know?cid=CS-ZC-FT-351676 Feb 01, 2019 - GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.

Pages: 12345678910...50

<<<Page 5>